Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Placebo-Controlled, Double-Dummy, Cross-Over Study to Investigate the Hypnotic Activity of Three Doses (10mg, 15mg, 20mg) of a New Zaleplon Prototype, SKP-1041, in Adults With Primary Insomnia

NCT00878553 is registered in ClinicalTrials.gov with Somnus Therapeutics, Inc. as lead sponsor.

NCT NCT00878553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00878553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Placebo-Controlled, Double-Dummy, Cross-Over Study to Investigate the Hypnotic Activity of Three Doses (10mg, 15mg, 20mg) of a New Zaleplon Prototype, SKP-1041, in Adults With Primary Insomnia
Lead sponsor
Somnus Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2010
Completion date
August 31, 2011
Enrollment
67 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary insomnia, sleep disorder